Inspire's Q1 2026 print attributes a combined $120 to $150 million FY26 hit to WISeR plus coding uncertainty, six sell-side analysts cut targets through 7 May, and NeuroPace just received a 43% to 47% Medicare reimbursement increase on the same rule cycle.
Newly filed federal disclosures show that Neuralink has engaged Jeffrey J. Kimbell & Associates and Arnold & Porter Kaye Scholer as its first registered federal lobbyists, with both firms beginning work at the end of April 2026. The scope explicitly names brain-computer interface development and commercialisation plus 'coverage of such devices' as the lobbying focus. The team on the Arnold & Porter side includes former 13-term Wisconsin Democratic Rep. Ron Kind, Senior Counsel at the firm since January 2024 and a former House Ways and Means Committee member overseeing Medicare payment programs. The hire is the first publicly visible step Neuralink has taken toward US Medicare reimbursement positioning for the N1 implant.
France's CEA-Leti announced on 3 June 2026 that it has applied for regulatory authorization to begin BCI4Stroke, a brain-computer interface clinical trial extending the WIMAGINE epidural implant platform into post-stroke rehabilitation. The trial is registered on ClinicalTrials.gov as NCT07477613. WIMAGINE is the same platform that produced the 2019 tetraplegic exoskeleton walking demonstration (Benabid et al., Lancet Neurology) and the 2023 brain-spine interface paralysed-man-walks result with Gert-Jan Oskam (Lorach et al., Nature, the Courtine and Bloch programme). BrainSync is funded under France's €40 million Audace! research programme (France 2030) and the European Innovation Council under Horizon Europe.
Eoin Egan, a 43-year-old Roscommon-born architect and property consultant living in London with motor neurone disease, has gone public as one of seven UK participants in Neuralink's GB-PRIME early feasibility study. Egan received his N1 Implant in December 2025 at UCLH's National Hospital for Neurology and Neurosurgery (Queen Square) in a six-hour robot-performed operation. Four days post-surgery he was driving his wheelchair through a London park with his thoughts alone, using bespoke software built by German assistive technology firm Homebrace that links the BCI cursor to wheelchair steering. He is the third UK GB-PRIME participant to surface publicly, after Paul (October 2025, also MND) and Sebastian Gomez (medical student paralysed in a diving accident).
Sydney and San Francisco-based Omniscient Neurotechnology closed a $27.2 million (AU$41.1 million) Series D funding round on 29 May 2026, co-led by OIF Ventures and the Australian National Reconstruction Fund Corporation. The capital scales the company's FDA-cleared Quicktome connectomics platform for neurosurgical planning, with the company explicitly naming brain-computer interface, stroke, and movement disorders as the next expansion indications. Omniscient is a connectomics company rather than a BCI implant company; the BCI angle is forward-looking adjacency rather than current product.
Rice University and Baylor College of Medicine announced on 28 May 2026 that they have joined the BrainGate research consortium, the multi-institutional clinical brain-computer interface network founded by John Donoghue at Brown University. The Texas team is the sixth in the consortium and the first based outside the eastern and western US clusters. The Rice-Baylor work focuses on decoding cortical neural signals to operate assistive robotic devices that help people with tetraplegia eat and drink independently. The expansion lands the same week Donoghue was named a 2026 Queen Elizabeth Prize for Engineering co-laureate for his BrainGate-anchored work.
Tencent Holdings has acquired a minority equity stake in Nanochap Electronics, a Hangzhou-based fabless semiconductor company specialising in neural interface and biosensing SoCs for brain-computer interface and medical device applications. The investment was disclosed through a 28 May 2026 business registration filing showing Shanghai Qishan Investment, a Tencent subsidiary, added as a new shareholder. Nanochap's registered capital increased to RMB 16.8853 million. Exact stake size and investment amount have not been publicly disclosed. The move follows the April 2026 StairMed funding round in which Alibaba led and Tencent joined, and signals a sustained pattern of Chinese big-tech equity participation in the country's BCI silicon supply chain.
Shanghai-based NeuroXess says a 35-year-old woman with epilepsy fitted with its 256-channel surface-cortex implant has been decoded reading Mandarin at 300 characters per minute through a large language model layer, faster than the roughly 220 cpm rate of a native Mandarin first-language speaker. Co-founder and chief scientist Tiger Tao disclosed the figure to Nature on 19 May 2026. The underlying paper has not yet been published, but the result sits on top of NeuroXess's already peer-reviewed Science Advances paper from 5 November 2025 (71.2% accuracy across 394 Mandarin syllables in a 43-year-old woman with epilepsy).
ONWARD Medical reported Q1 2026 results on 26 May 2026 with EUR 2.0 million in revenue (EUR 1.3 million ARC-EX systems across 100+ clinics, 70 systems supplied including first home-use shipments to US VA patients), two additional ARC-BCI participants bringing the total to seven, and first participant enrolled plus first implant in the Empower BP pivotal study at Craig Hospital, Denver. The company holds EUR 53.4 million in cash before adding over EUR 40 million from the April equity raise, extending runway into Q1 2028.
Get the latest BCI news, breakthroughs, and market moves delivered to your inbox.
No spam. One-click unsubscribe. We respect your privacy.